<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>13</Volume>
				<Issue>12</Issue>
				<PubDate PubStatus="epublish">
					<Year>2012</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Complement Receptor 1 Expression in Peripheral Blood Mononuclear Cells and the Association with Clinicopathological Features And Prognosis of Nasopharyngeal Carcinoma</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>6527</FirstPage>
			<LastPage>6531</LastPage>
			<ELocationID EIdType="pii">27268</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Purpose: Complement receptor 1 (CR1) is induced by Epstein-Barr virus (EBV) and may be a potentialbiomarker of nasopharyngeal carcinoma (NPC). We conducted the present study to evaluate the association ofCR1 expression with clinicopathological features and prognosis of NPC. &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: We enrolled 145 NPC patientsand 110 controls. Expression levels of CR1 in peripheral blood mononuclear cells (PBMCs) were detected usingquantitative real-time PCR and associations with clinicopathological features and prognosis were examined.&lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: CR1 levels in the NPC group [3.54 (3.34, 3.79)] were slightly higher than those in the controls [3.33(3.20, 3.47)] (P&lt;0.001). Increased CR1 expression was associated with histology classification (type III vs. typeII, P=0.002), advanced clinical stage (P=0.003), high T stage (P=0.017), and poor overall survival (HR, 4.89; 95%CI, 1.23-19.42; P=0.024). However, there were no statistically significant differences in CR1 expression amongN or M stages. &lt;br/&gt;&lt;b&gt;Conclusion&lt;/b&gt;: These findings indicate that CR1 expression in PBMCs may be a new biomarker forprognosis of NPC and a potential therapeutic target.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Complement receptor 1</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">mRNA expression</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">NPC</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">PBMCs</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Prognosis</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_27268_93cfb13496fad5c2aa6e38ebdc57dfed.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
